Literature DB >> 2279990

Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus.

J C Lee1, M J Liu, J Parsonnet, R D Arbeit.   

Abstract

A colony immunoblot method was developed for serotyping the capsular polysaccharides expressed by Staphylococcus aureus isolates. The method was rapid and specific and was performed with either polyclonal or monoclonal antibodies specific for each of the capsule types. S. aureus isolates were obtained from patients with toxic shock syndrome (TSS) or other staphylococcal infections and from asymptomatic women with vaginal colonization. Among the vaginal isolates of S. aureus, expression of the type 8 capsule was significantly (P less than 0.001) more frequent among strains that produced TSS toxin 1 (TSST-1) than it was among TSST-1-negative strains. In contrast, the frequency of type 8 capsule expression was similar among both TSST-1-positive and -negative strains of S. aureus from patients with nonvaginal TSS. When all vaginal and nonvaginal isolates were compared, TSST-1-negative S. aureus strains were equally distributed among the type 5 and 8 and nontypeable capsule groups, whereas TSST-1-positive strains were predominantly capsule type 8.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2279990      PMCID: PMC268243          DOI: 10.1128/jcm.28.12.2612-2615.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  PRODUCTION OF LARGE QUANTITIES OF ENTEROTOXIN B AND OTHER STAPHYLOCOCCAL TOXINS ON SOLID MEDIA.

Authors:  H O HALLANDER
Journal:  Acta Pathol Microbiol Scand       Date:  1965

2.  Phenotypic distinctiveness of Staphylococcus aureus strains associated with toxic shock syndrome.

Authors:  J K Todd; A Franco-Buff; D W Lawellin; M L Vasil
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

3.  Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus.

Authors:  R D Arbeit; W W Karakawa; W F Vann; J B Robbins
Journal:  Diagn Microbiol Infect Dis       Date:  1984-04       Impact factor: 2.803

4.  Toxic shock syndrome: modification and comparison of methods for detecting marker proteins in Staphylococcus aureus.

Authors:  M L Cohen; L M Graves; P S Hayes; R J Gibson; J K Rasheed; J C Feeley
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

5.  Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.

Authors:  P M Schlievert; K N Shands; B B Dan; G P Schmid; R D Nishimura
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

6.  Toxic shock syndrome surveillance in the United States, 1980 to 1981.

Authors:  A L Reingold; N T Hargrett; K N Shands; B B Dan; G P Schmid; B Y Strickland; C V Broome
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

7.  Comparative observations of fever and associated clinical hematological and blood biochemical changes after intravenous administration of staphylococcal enterotoxins B and F (toxic shock syndrome toxin-1) in goats.

Authors:  A S Van Miert; C T Van Duin; A J Schotman
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

8.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

Authors:  A Albus; J M Fournier; C Wolz; A Boutonnier; M Ranke; N Høiby; H Hochkeppel; G Döring
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

9.  Vaginal isolates of Staphylococcus aureus associated with toxic shock syndrome.

Authors:  A G Barbour
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

10.  A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome.

Authors:  J M Musser; P M Schlievert; A W Chow; P Ewan; B N Kreiswirth; V T Rosdahl; A S Naidu; W Witte; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

View more
  30 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Capsule expression by bovine isolates of Staphylococcus aureus from Argentina: genetic and epidemiologic analyses.

Authors:  D O Sordelli; F R Buzzola; M I Gomez; L Steele-Moore; D Berg; E Gentilini; M Catalano; A J Reitz; T Tollersrud; G Denamiel; P Jeric; J C Lee
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Identification of the capsular polysaccharides in Staphylococcus aureus clinical isolates by PCR and agglutination tests.

Authors:  Isabelle Verdier; Geraldine Durand; Michele Bes; Kimberly L Taylor; Gerard Lina; François Vandenesch; Ali I Fattom; Jerome Etienne
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

4.  Rapid and reliable identification of Staphylococcus aureus capsular serotypes by means of artificial neural network-assisted Fourier transform infrared spectroscopy.

Authors:  Tom Grunert; Mareike Wenning; María Sol Barbagelata; Martina Fricker; Daniel O Sordelli; Fernanda R Buzzola; Monika Ehling-Schulz
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

5.  Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

6.  Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis.

Authors:  Santiago M Lattar; Mariángeles Noto Llana; Philippe Denoël; Sophie Germain; Fernanda R Buzzola; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

7.  Capsule-negative Staphylococcus aureus induces chronic experimental mastitis in mice.

Authors:  Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Roberto L Caccuri; Jean C Lee; Daniel O Sordelli
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Salicylic acid diminishes Staphylococcus aureus capsular polysaccharide type 5 expression.

Authors:  Lucía P Alvarez; María S Barbagelata; Mariana Gordiola; Ambrose L Cheung; Daniel O Sordelli; Fernanda R Buzzola
Journal:  Infect Immun       Date:  2009-12-14       Impact factor: 3.441

9.  Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.

Authors:  A Albus; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

10.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.